Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed, Inc. stock logo
INSM
Insmed
$131.88
-0.5%
$107.48
$60.40
$133.56
$28.03B0.953.22 million shs2.10 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$37.01
+1.5%
$37.48
$29.17
$62.40
$6.82B1.161.90 million shs1.09 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$26.20
+0.7%
$25.02
$11.76
$36.91
$19.32B-1.062.81 million shs2.22 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$18.47
-1.8%
$16.75
$12.47
$22.80
$21.56B0.6213.18 million shs13.29 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed, Inc. stock logo
INSM
Insmed
-0.54%+3.19%+27.49%+95.29%+71.25%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+1.45%+1.90%-1.39%-6.94%-18.26%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.73%-1.84%-6.46%+1.35%+96.40%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-1.73%+3.39%+11.41%+8.98%+1.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Insmed, Inc. stock logo
INSM
Insmed
4.0046 of 5 stars
2.54.00.04.33.80.80.6
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.4106 of 5 stars
4.51.00.04.73.41.70.0
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.3768 of 5 stars
4.31.00.00.01.91.70.0
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
3.4317 of 5 stars
3.64.00.00.03.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Insmed, Inc. stock logo
INSM
Insmed
2.94
Moderate Buy$132.570.52% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$69.9288.93% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.63
Moderate Buy$32.8525.37% Upside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
3.25
Buy$24.7133.84% Upside

Current Analyst Ratings Breakdown

Latest RVMD, INSM, TEVA, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$126.00 ➝ $144.00
8/20/2025
Insmed, Inc. stock logo
INSM
Insmed
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$111.00 ➝ $135.00
8/20/2025
Insmed, Inc. stock logo
INSM
Insmed
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
8/19/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Summit Redstone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$21.00
8/19/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$40.00
8/18/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$75.00
8/18/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$21.00
8/18/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$80.00
8/15/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$67.00
8/15/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00
8/14/2025
Insmed, Inc. stock logo
INSM
Insmed
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$126.00 ➝ $139.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Insmed, Inc. stock logo
INSM
Insmed
$363.71M76.65N/AN/A$5.91 per share22.31
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M597.43N/AN/A$9.98 per share3.71
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$700K27,803.81N/AN/A$0.35 per share74.86
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B1.28$3.30 per share5.59$5.96 per share3.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$0.16N/A7.021.11-0.95%46.10%7.18%11/5/2025 (Estimated)

Latest RVMD, INSM, TEVA, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10-$0.76-$0.66-$0.76N/AN/A
8/7/2025Q2 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million
8/6/2025Q2 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A
7/30/2025Q2 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.64$0.66+$0.02$0.24$4.34 billion$4.18 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Insmed, Inc. stock logo
INSM
Insmed
0.45
6.68
6.33
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.13
11.79
11.79
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
5.13
5.13
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.45
1.06
0.77

Institutional Ownership

CompanyInstitutional Ownership
Insmed, Inc. stock logo
INSM
Insmed
N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
Insmed, Inc. stock logo
INSM
Insmed
3.00%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8.20%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
84.90%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,271211.38 million205.03 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.93 million171.60 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110742.85 million112.17 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
36,8301.15 billion1.14 billionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Insmed stock logo

Insmed NASDAQ:INSM

$131.88 -0.72 (-0.54%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$131.76 -0.13 (-0.09%)
As of 08/22/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$37.01 +0.53 (+1.45%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$37.40 +0.39 (+1.05%)
As of 08/22/2025 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$26.20 +0.19 (+0.73%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$26.40 +0.20 (+0.75%)
As of 08/22/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$18.47 -0.33 (-1.78%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$18.60 +0.13 (+0.73%)
As of 08/22/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.